Cannabidiol (Epidyolex®). HTA ID: 20005

Assessment Status NCPE Assessment Process complete
HTA ID 20005
Drug Cannabidiol
Brand Epidyolex®
Indication As adjunctive therapy of seizures associated with Lennox-Gastaut Syndrome in conjunction with clobazam, for patients two years of age and older.
Assessment Process
Rapid review commissioned 05/02/2020
Rapid review completed 11/03/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cannabidiol compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 16/03/2020
Pre-submission consultation with Applicant 27/04/2020
Full submission received from Applicant 14/07/2020
Preliminary review sent to Applicant 13/11/2020
NCPE assessment re-commenced 22/12/2020
Factual accuracy sent to Applicant 05/02/2021
NCPE assessment re-commenced 12/02/2021
NCPE assessment completed 08/03/2021
NCPE assessment outcome The NCPE recommends that cannabidiol (Epidyolex®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations December 2021.

Technical Summary

Plain English Summary